SlideShare a Scribd company logo
PRESENTATION BY 
DR. MUHAMMAD UMAIR
Review article 
The new england journal of medicine 
Assessing Kidney Function- 
Measured and Estimated 
Glomerular Filtration Rate 
Lesley A. Stevens, M.D., Josef Coresh, M.D., Ph.D., Tom Greene, Ph.D., 
and Andrew S. Levey, M.D.
the strengths and weaknesses 
of current methods of measuring 
and estimating GFR as applied to 
chronic kidney disease.
Chronic Kidney Disease 
A persistent reduction in the GFR to less than 60 
ml per minute per 1.73m2of body-surface area 
or 
the presence of kidney damage, regardless of 
the cause, for three or more months. 
Risk factors: 
an age of more than 60 years, hypertension, 
diabetes, cardiovascular disease, and a family 
history of the disease.
Measurement of GFR with 
Filtration Markers 
(urinary or plasma clearance) 
• Exogenous: inulin,iothalamate,EDTA, and 
iohexol. 
• Endogenous: Creatinine, Cystatin C
EXOGENOUS MARKERS CLEARANCE
ENDOGENOUS MARKERS: 
Creatinine 
• Urinary clearance: 
timed urine collection 
• blood sampling during 
the collection period 
• Creatinine clearance 
has reciprocal 
relationship with the 
serum creatinine level. 
• Drugs, trimethoprim & 
cimetidine clearance 
and serum level 
• the relationship 
between the levels of 
serum creatinine and 
GFR varies among 
persons & over time.
Cystatin C 
• Reabsorbed and catabolized by the tubular 
epithelial cells; only small amounts are 
excreted in the urine so its urinary clearance 
cannot be measured. 
• The generation of cystatin C appears to be less 
variable from person to person than that of 
creatinine. 
• However, serum levels are Influenced by 
corticosteroid use and related to age, sex, 
weight, height, smoking status, and the level of 
C-reactive protein.
Estimation of GFR with Equations 
Two creatinine-based equations 
• The Cockcroft–Gault equation i.e 
Ccr = [(140 − age) × weight]/(72 × Scr ) × 0.85 (if the subject is female) 
• The Modification of Diet in Renal Disease 
(MDRD) study equation i.e 
GFR = 186 × (Scr)−1.154 × (age)−0.203 × 0.742 (if the subject is female) 
or × 1.212 (if the subject is black). 
It estimates GFR adjusted for body-surface area. It was found to be 
more accurate.
Evaluation of Current Estimating Equations 
• In some studies the MDRD study equation has 
been reported to be more accurate than the 
Cockcroft–Gault equation but not in other. 
• The Cockcroft–Gault equation appears to be less 
accurate than the MDRD study equation in older 
and obese people 
• The MDRD study equation is reasonably accurate 
in nonhospitalized patients known to have chronic 
kidney disease 
• Both the MDRD study and the Cockcroft–Gault 
equations have been reported to be less accurate 
in populations without chronic kidney disease.
Use of GFR Estimates 
• Detection of Chronic Kidney Disease 
• Monitoring Progression of Chronic Kidney 
Disease 
• Evaluation and Management of Complications 
• GFR and Referral to Nephrologists 
• Medications and Chronic Kidney Disease 
• Assessment of Risk for Cardiovascular Disease
When to Consider Clearance Measurements Instead 
of Estimated GFR 
When more accurate estimates 
may be necessary 
• to evaluate people for kidney donation, 
• to administer drugs (e.g.methotrexate), or 
• for research protocols. 
Clearance of exogenous filtration markers provides 
the most accurate measure of GFR
GFR Reporting by Clinical Laboratories 
• Laboratories should report a specific value 
of GFR only if the estimated GFR is less than 
60 ml per minute per 1.73 m2 
• Higher values should be reported as “GFR is 
60 ml per minute per 1.73 m2 or more.
Conclusions 
• The main limitation of current GFR estimates is 
the greater inaccuracy in populations without 
known chronic kidney disease than in those with 
the disease. 
• However current GFR estimates 
facilitate detection, evaluation, and management 
of the disease.
Assessing kidney function — measured

More Related Content

What's hot

Renal Replacement therapy
Renal Replacement therapyRenal Replacement therapy
Renal Replacement therapy
Dr Amber Z Jafferi
 
E Gfr 2008
E Gfr  2008E Gfr  2008
E Gfr 2008
atbeat
 
The Kidney Transplantation Patient Pathway at the QEHB
The Kidney Transplantation Patient Pathway at the QEHBThe Kidney Transplantation Patient Pathway at the QEHB
The Kidney Transplantation Patient Pathway at the QEHBmeducationdotnet
 
Advancing dialysis - Improving Outcomes for Dialysis Patients
Advancing dialysis - Improving Outcomes for Dialysis PatientsAdvancing dialysis - Improving Outcomes for Dialysis Patients
Advancing dialysis - Improving Outcomes for Dialysis Patients
nxstage
 
Advancing dialysis multinational guidelines for increased time and frequency ...
Advancing dialysis multinational guidelines for increased time and frequency ...Advancing dialysis multinational guidelines for increased time and frequency ...
Advancing dialysis multinational guidelines for increased time and frequency ...
AdvancingDialysis.org
 
Advancing Dialysis Recent Findings: PD first ... what's next?
Advancing Dialysis Recent Findings: PD first ... what's next?Advancing Dialysis Recent Findings: PD first ... what's next?
Advancing Dialysis Recent Findings: PD first ... what's next?
AdvancingDialysis.org
 
When to Initiate RRT in Patients with AKI - Does Timing Matter?
When to Initiate RRT in Patients with AKI - Does Timing Matter?When to Initiate RRT in Patients with AKI - Does Timing Matter?
When to Initiate RRT in Patients with AKI - Does Timing Matter?
Apollo Hospitals
 
Nov journal watch
Nov journal watchNov journal watch
Nov journal watch
katejohnpunag
 
Cards研究 糖尿病
Cards研究 糖尿病Cards研究 糖尿病
Cards研究 糖尿病
celebox
 
Advancing dialysis.org recent findings better management of volume with inten...
Advancing dialysis.org recent findings better management of volume with inten...Advancing dialysis.org recent findings better management of volume with inten...
Advancing dialysis.org recent findings better management of volume with inten...
AdvancingDialysis.org
 
When to Initiate RRT in Patients with AKI - Does Timing Matter?
When to Initiate RRT in Patients with AKI - Does Timing Matter?When to Initiate RRT in Patients with AKI - Does Timing Matter?
When to Initiate RRT in Patients with AKI - Does Timing Matter?
Apollo Hospitals
 
Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICU Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICU
Syed Hussain
 
When to initiate RRT in patients with AKI - Does timing matter?
When to initiate RRT in patients with AKI - Does timing matter?When to initiate RRT in patients with AKI - Does timing matter?
When to initiate RRT in patients with AKI - Does timing matter?Apollo Hospitals
 
Acute pancreatitis
Acute pancreatitisAcute pancreatitis
Acute pancreatitis
Apollo Hospitals
 
Initiation And Incremental Dialysis
Initiation And Incremental DialysisInitiation And Incremental Dialysis
Initiation And Incremental Dialysis
edwinchowyw
 
Serum Creatinine, muscle mass and mortality
Serum Creatinine, muscle mass and mortalitySerum Creatinine, muscle mass and mortality
Serum Creatinine, muscle mass and mortality
Wisit Cheungpasitporn
 
Drug modification in crrt
Drug modification in crrt Drug modification in crrt
Drug modification in crrt
krishnaswamy sampathkumar
 
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
International Fluid Academy
 
Renal updates oct 2014 plumb
Renal updates oct 2014 plumbRenal updates oct 2014 plumb
Renal updates oct 2014 plumb
Steve Mathieu
 

What's hot (20)

Renal Replacement therapy
Renal Replacement therapyRenal Replacement therapy
Renal Replacement therapy
 
E Gfr 2008
E Gfr  2008E Gfr  2008
E Gfr 2008
 
The Kidney Transplantation Patient Pathway at the QEHB
The Kidney Transplantation Patient Pathway at the QEHBThe Kidney Transplantation Patient Pathway at the QEHB
The Kidney Transplantation Patient Pathway at the QEHB
 
2010 uptodate adequacy dp
2010 uptodate adequacy dp2010 uptodate adequacy dp
2010 uptodate adequacy dp
 
Advancing dialysis - Improving Outcomes for Dialysis Patients
Advancing dialysis - Improving Outcomes for Dialysis PatientsAdvancing dialysis - Improving Outcomes for Dialysis Patients
Advancing dialysis - Improving Outcomes for Dialysis Patients
 
Advancing dialysis multinational guidelines for increased time and frequency ...
Advancing dialysis multinational guidelines for increased time and frequency ...Advancing dialysis multinational guidelines for increased time and frequency ...
Advancing dialysis multinational guidelines for increased time and frequency ...
 
Advancing Dialysis Recent Findings: PD first ... what's next?
Advancing Dialysis Recent Findings: PD first ... what's next?Advancing Dialysis Recent Findings: PD first ... what's next?
Advancing Dialysis Recent Findings: PD first ... what's next?
 
When to Initiate RRT in Patients with AKI - Does Timing Matter?
When to Initiate RRT in Patients with AKI - Does Timing Matter?When to Initiate RRT in Patients with AKI - Does Timing Matter?
When to Initiate RRT in Patients with AKI - Does Timing Matter?
 
Nov journal watch
Nov journal watchNov journal watch
Nov journal watch
 
Cards研究 糖尿病
Cards研究 糖尿病Cards研究 糖尿病
Cards研究 糖尿病
 
Advancing dialysis.org recent findings better management of volume with inten...
Advancing dialysis.org recent findings better management of volume with inten...Advancing dialysis.org recent findings better management of volume with inten...
Advancing dialysis.org recent findings better management of volume with inten...
 
When to Initiate RRT in Patients with AKI - Does Timing Matter?
When to Initiate RRT in Patients with AKI - Does Timing Matter?When to Initiate RRT in Patients with AKI - Does Timing Matter?
When to Initiate RRT in Patients with AKI - Does Timing Matter?
 
Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICU Renal Replacement therapy in the ICU
Renal Replacement therapy in the ICU
 
When to initiate RRT in patients with AKI - Does timing matter?
When to initiate RRT in patients with AKI - Does timing matter?When to initiate RRT in patients with AKI - Does timing matter?
When to initiate RRT in patients with AKI - Does timing matter?
 
Acute pancreatitis
Acute pancreatitisAcute pancreatitis
Acute pancreatitis
 
Initiation And Incremental Dialysis
Initiation And Incremental DialysisInitiation And Incremental Dialysis
Initiation And Incremental Dialysis
 
Serum Creatinine, muscle mass and mortality
Serum Creatinine, muscle mass and mortalitySerum Creatinine, muscle mass and mortality
Serum Creatinine, muscle mass and mortality
 
Drug modification in crrt
Drug modification in crrt Drug modification in crrt
Drug modification in crrt
 
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
7. (r)evolution in liver failure in critically ill #uzb40 icu (wilmer)
 
Renal updates oct 2014 plumb
Renal updates oct 2014 plumbRenal updates oct 2014 plumb
Renal updates oct 2014 plumb
 

Viewers also liked

Prof. el nahas.what is new in ckd.
Prof. el nahas.what is new in ckd.Prof. el nahas.what is new in ckd.
Prof. el nahas.what is new in ckd.wessam1071
 
Aki icu
Aki icuAki icu
Creatinine clearance: When Does It Matter?
Creatinine clearance: When Does It Matter?Creatinine clearance: When Does It Matter?
Creatinine clearance: When Does It Matter?
PASaskatchewan
 
35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokineticsDang Thanh Tuan
 
Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerations
Dr Htet
 

Viewers also liked (6)

Prof. el nahas.what is new in ckd.
Prof. el nahas.what is new in ckd.Prof. el nahas.what is new in ckd.
Prof. el nahas.what is new in ckd.
 
Aki icu
Aki icuAki icu
Aki icu
 
Creatinine clearance: When Does It Matter?
Creatinine clearance: When Does It Matter?Creatinine clearance: When Does It Matter?
Creatinine clearance: When Does It Matter?
 
35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics
 
Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerations
 
Medication error
Medication errorMedication error
Medication error
 

Similar to Assessing kidney function — measured

Approach to Chronic Kidney Diseases
Approach to Chronic Kidney DiseasesApproach to Chronic Kidney Diseases
Approach to Chronic Kidney Diseases
Beka Aberra
 
JOURNAL CLUB PRESENTATION 191222 edirted.pptx
JOURNAL CLUB PRESENTATION 191222 edirted.pptxJOURNAL CLUB PRESENTATION 191222 edirted.pptx
JOURNAL CLUB PRESENTATION 191222 edirted.pptx
JyotiSharma560718
 
Drug dosage adjustment using renal estimation equations. A review of the lite...
Drug dosage adjustment using renal estimation equations. A review of the lite...Drug dosage adjustment using renal estimation equations. A review of the lite...
Drug dosage adjustment using renal estimation equations. A review of the lite...Greenberg, Eric
 
Pcp in a box module 1
Pcp in a box   module 1Pcp in a box   module 1
Pcp in a box module 1
MohibaAgha
 
injuria renal 4.pptx
injuria renal 4.pptxinjuria renal 4.pptx
injuria renal 4.pptx
MartyMcfly25
 
ICU presentation - Hannah Bond and Kim Treier
ICU presentation - Hannah Bond and Kim TreierICU presentation - Hannah Bond and Kim Treier
ICU presentation - Hannah Bond and Kim TreierKimberly Treier
 
Chronic kidney disease how a deeper understanding of the disease is impacting...
Chronic kidney disease how a deeper understanding of the disease is impacting...Chronic kidney disease how a deeper understanding of the disease is impacting...
Chronic kidney disease how a deeper understanding of the disease is impacting...
Medpace
 
KIDNEY FUNCTION TEST
KIDNEY FUNCTION TESTKIDNEY FUNCTION TEST
KIDNEY FUNCTION TEST
Premal Vaghela
 
Dose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failureDose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failure
Pallavi Kurra
 
The aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about itThe aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about it
Christos Argyropoulos
 
The aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about itThe aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about it
Christos Argyropoulos
 
Chronic renal failure update on diagnostic tests
Chronic renal failure update on diagnostic testsChronic renal failure update on diagnostic tests
Chronic renal failure update on diagnostic tests
Dr. Rajesh Bendre
 
Cystatin-C-as-a-Marker-of-Renal-Function.pptx
Cystatin-C-as-a-Marker-of-Renal-Function.pptxCystatin-C-as-a-Marker-of-Renal-Function.pptx
Cystatin-C-as-a-Marker-of-Renal-Function.pptx
DrRhutaShah1
 
Hepatorenal Syndrome
Hepatorenal Syndrome Hepatorenal Syndrome
Hepatorenal Syndrome
Pratap Tiwari
 
Pitfalls in estimating renal failure in the elderly by eGFR
Pitfalls in estimating renal failure in the elderly by eGFRPitfalls in estimating renal failure in the elderly by eGFR
Pitfalls in estimating renal failure in the elderly by eGFR
Ranjit Singh
 
JC discussion
JC discussionJC discussion
JC discussion
Parikh6
 
A critical review on an article
A critical review on an articleA critical review on an article
A critical review on an article
Cihan Durmuş Saydam
 
.-Renal Evaluation and Protection.pdf
.-Renal Evaluation and Protection.pdf.-Renal Evaluation and Protection.pdf
.-Renal Evaluation and Protection.pdf
juandavid446
 
End stage renal disease
End stage renal diseaseEnd stage renal disease
End stage renal disease
Prasenjit Gogoi
 

Similar to Assessing kidney function — measured (20)

Approach to Chronic Kidney Diseases
Approach to Chronic Kidney DiseasesApproach to Chronic Kidney Diseases
Approach to Chronic Kidney Diseases
 
JOURNAL CLUB PRESENTATION 191222 edirted.pptx
JOURNAL CLUB PRESENTATION 191222 edirted.pptxJOURNAL CLUB PRESENTATION 191222 edirted.pptx
JOURNAL CLUB PRESENTATION 191222 edirted.pptx
 
Kideny function test
Kideny function testKideny function test
Kideny function test
 
Drug dosage adjustment using renal estimation equations. A review of the lite...
Drug dosage adjustment using renal estimation equations. A review of the lite...Drug dosage adjustment using renal estimation equations. A review of the lite...
Drug dosage adjustment using renal estimation equations. A review of the lite...
 
Pcp in a box module 1
Pcp in a box   module 1Pcp in a box   module 1
Pcp in a box module 1
 
injuria renal 4.pptx
injuria renal 4.pptxinjuria renal 4.pptx
injuria renal 4.pptx
 
ICU presentation - Hannah Bond and Kim Treier
ICU presentation - Hannah Bond and Kim TreierICU presentation - Hannah Bond and Kim Treier
ICU presentation - Hannah Bond and Kim Treier
 
Chronic kidney disease how a deeper understanding of the disease is impacting...
Chronic kidney disease how a deeper understanding of the disease is impacting...Chronic kidney disease how a deeper understanding of the disease is impacting...
Chronic kidney disease how a deeper understanding of the disease is impacting...
 
KIDNEY FUNCTION TEST
KIDNEY FUNCTION TESTKIDNEY FUNCTION TEST
KIDNEY FUNCTION TEST
 
Dose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failureDose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failure
 
The aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about itThe aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about it
 
The aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about itThe aging kidney and what we should (not?) do about it
The aging kidney and what we should (not?) do about it
 
Chronic renal failure update on diagnostic tests
Chronic renal failure update on diagnostic testsChronic renal failure update on diagnostic tests
Chronic renal failure update on diagnostic tests
 
Cystatin-C-as-a-Marker-of-Renal-Function.pptx
Cystatin-C-as-a-Marker-of-Renal-Function.pptxCystatin-C-as-a-Marker-of-Renal-Function.pptx
Cystatin-C-as-a-Marker-of-Renal-Function.pptx
 
Hepatorenal Syndrome
Hepatorenal Syndrome Hepatorenal Syndrome
Hepatorenal Syndrome
 
Pitfalls in estimating renal failure in the elderly by eGFR
Pitfalls in estimating renal failure in the elderly by eGFRPitfalls in estimating renal failure in the elderly by eGFR
Pitfalls in estimating renal failure in the elderly by eGFR
 
JC discussion
JC discussionJC discussion
JC discussion
 
A critical review on an article
A critical review on an articleA critical review on an article
A critical review on an article
 
.-Renal Evaluation and Protection.pdf
.-Renal Evaluation and Protection.pdf.-Renal Evaluation and Protection.pdf
.-Renal Evaluation and Protection.pdf
 
End stage renal disease
End stage renal diseaseEnd stage renal disease
End stage renal disease
 

Assessing kidney function — measured

  • 1. PRESENTATION BY DR. MUHAMMAD UMAIR
  • 2. Review article The new england journal of medicine Assessing Kidney Function- Measured and Estimated Glomerular Filtration Rate Lesley A. Stevens, M.D., Josef Coresh, M.D., Ph.D., Tom Greene, Ph.D., and Andrew S. Levey, M.D.
  • 3. the strengths and weaknesses of current methods of measuring and estimating GFR as applied to chronic kidney disease.
  • 4. Chronic Kidney Disease A persistent reduction in the GFR to less than 60 ml per minute per 1.73m2of body-surface area or the presence of kidney damage, regardless of the cause, for three or more months. Risk factors: an age of more than 60 years, hypertension, diabetes, cardiovascular disease, and a family history of the disease.
  • 5. Measurement of GFR with Filtration Markers (urinary or plasma clearance) • Exogenous: inulin,iothalamate,EDTA, and iohexol. • Endogenous: Creatinine, Cystatin C
  • 7. ENDOGENOUS MARKERS: Creatinine • Urinary clearance: timed urine collection • blood sampling during the collection period • Creatinine clearance has reciprocal relationship with the serum creatinine level. • Drugs, trimethoprim & cimetidine clearance and serum level • the relationship between the levels of serum creatinine and GFR varies among persons & over time.
  • 8.
  • 9. Cystatin C • Reabsorbed and catabolized by the tubular epithelial cells; only small amounts are excreted in the urine so its urinary clearance cannot be measured. • The generation of cystatin C appears to be less variable from person to person than that of creatinine. • However, serum levels are Influenced by corticosteroid use and related to age, sex, weight, height, smoking status, and the level of C-reactive protein.
  • 10. Estimation of GFR with Equations Two creatinine-based equations • The Cockcroft–Gault equation i.e Ccr = [(140 − age) × weight]/(72 × Scr ) × 0.85 (if the subject is female) • The Modification of Diet in Renal Disease (MDRD) study equation i.e GFR = 186 × (Scr)−1.154 × (age)−0.203 × 0.742 (if the subject is female) or × 1.212 (if the subject is black). It estimates GFR adjusted for body-surface area. It was found to be more accurate.
  • 11. Evaluation of Current Estimating Equations • In some studies the MDRD study equation has been reported to be more accurate than the Cockcroft–Gault equation but not in other. • The Cockcroft–Gault equation appears to be less accurate than the MDRD study equation in older and obese people • The MDRD study equation is reasonably accurate in nonhospitalized patients known to have chronic kidney disease • Both the MDRD study and the Cockcroft–Gault equations have been reported to be less accurate in populations without chronic kidney disease.
  • 12.
  • 13. Use of GFR Estimates • Detection of Chronic Kidney Disease • Monitoring Progression of Chronic Kidney Disease • Evaluation and Management of Complications • GFR and Referral to Nephrologists • Medications and Chronic Kidney Disease • Assessment of Risk for Cardiovascular Disease
  • 14.
  • 15. When to Consider Clearance Measurements Instead of Estimated GFR When more accurate estimates may be necessary • to evaluate people for kidney donation, • to administer drugs (e.g.methotrexate), or • for research protocols. Clearance of exogenous filtration markers provides the most accurate measure of GFR
  • 16. GFR Reporting by Clinical Laboratories • Laboratories should report a specific value of GFR only if the estimated GFR is less than 60 ml per minute per 1.73 m2 • Higher values should be reported as “GFR is 60 ml per minute per 1.73 m2 or more.
  • 17. Conclusions • The main limitation of current GFR estimates is the greater inaccuracy in populations without known chronic kidney disease than in those with the disease. • However current GFR estimates facilitate detection, evaluation, and management of the disease.